Analysis of the response and toxicity to gefitinib of non-small cell lung cancer.


BACKGROUND Gefitinib is an oral agent that inhibits the tyrosine kinase of epidermal growth factor receptor (EGFR), which had antitumor activity in patients with previously treated non-small cell lung cancer (NSCLC). We analyzed the efficacy, toxicity and overall survival time of gefitinib treatment in patients with NSCLC. PATIENTS AND METHODS One hundred… (More)


2 Figures and Tables